RecruitingEarly Phase 1NCT07162012

Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma

Studying Epstein-Barr virus-positive diffuse large B-cell lymphoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Intervention
EBV TCR-T(drug)
Enrollment
24 enrolled
Eligibility
18-70 years · All sexes
Timeline
20252029

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07162012 on ClinicalTrials.gov

Other trials for Epstein-Barr virus-positive diffuse large B-cell lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Epstein-Barr virus-positive diffuse large B-cell lymphoma

← Back to all trials